Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)

Gladman, Dafna D.; Schentag, Catherine T.; Tom, Brian D. M.; Chandran, Vinod; Brockbank, John; Rosen, Cheryl F.; Farewell, Vernon T.

doi:10.1136/ard.2008.089441

Cited by 172 publications

(146 citation statements)

References 11 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Simple and validated screening tests, such as the Psoriatic Arthritis Screening and Evaluation (PASE) tool, the Psoriasis Epidemiology Screening Tool (PEST), the Toronto Psoriatic Arthritis Screen (ToPAS) and the Early ARthritis for Psoriatic patients (EARP) questionnaire, have been assessed to determine whether people with suspected PsA should be referred to confirm the diagnosis (Table 1). 16, 17, 18, 19 Despite such tools, the paucity of data from secondary care regarding their feasibility, sensitivity and specificity, along with the lack of consensus on which tool is best, hampers their widespread clinical use. In some cases the sensitivities and specificities of the tools have been found to be lower than originally reported; when the PASE, PEST and ToPAS questionnaires were compared in the CONTEST study, it was found that they would identify cases of musculoskeletal disease other than PsA, and there was little difference between the performance of the tools 20…”

Section: Overcoming Barriers To the Early And Accurate Diagnosis Of Psamentioning

confidence: 99%

Promoting patient‐centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience

Betteridge

Boehncke

Bundy

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

Patients with psoriatic arthritis (PsA) may not be optimally treated. The impact of the disease extends beyond skin and joint symptoms, impairing quality of life. This indicates that the adoption of a patient‐focused approach to PsA management is necessary. An expert multidisciplinary working group was convened, with the objective of developing an informed perspective on current best practice and needs for the future management of PsA. Topics of discussion included the barriers to current best practice and calls to action for the improvement of three areas in PsA management: early and accurate diagnosis of PsA, management of disease progression and management of the impact of the condition on the patient. The working group agreed that, to make best use of the available of diagnostic tools, clinical care recommendations and effective treatments, there is a clear need for healthcare professionals from different disciplines to collaborate in the management of PsA. By facilitating appropriate and rapid referral, providing high quality information about PsA and its treatment to patients, and actively involving patients when choosing management plans and setting treatment goals, management of PsA can be improved. The perspective of the working group is presented here, with recommendations for the adoption of a multidisciplinary, patient‐focused approach to the management of PsA.

show abstract

Section: Overcoming Barriers To the Early And Accurate Diagnosis Of Psamentioning

confidence: 99%

Promoting patient‐centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience

Betteridge

Boehncke

Bundy

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…3 Moll and Wright concluded from a review of epidemiological studies and scientifically support the concept that psoriatic arthritis is a single entity, with clinical, serological and radiological characteristics, and provided the earliest diagnostic criteria for psoriatic arthritis. [4][5][6] Nowadays it is generally agreed that while psoriatic arthritis can be classified among spondyloarthropathies, a family of disorders sharing common features like inflammatory arthritis, axial involvement, enthesopathy, absence of rheumatoid factor and association with HLA. 5,6 There is no general agreement in the literature regarding the prevalence of psoriatic arthritis.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6] Nowadays it is generally agreed that while psoriatic arthritis can be classified among spondyloarthropathies, a family of disorders sharing common features like inflammatory arthritis, axial involvement, enthesopathy, absence of rheumatoid factor and association with HLA. 5,6 There is no general agreement in the literature regarding the prevalence of psoriatic arthritis. The estimate of prevalence has been difficult because of the paucity of widely accepted classification or diagnostic criteria and the difficulty of most experts in making a correct diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasília

Carneiro¹,

Paula

Martins

2012

An. Bras. Dermatol.

View full text Add to dashboard Cite

BACKGROUND: Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. Its prevalence in patients with psoriasis varies from 7 to 42% but its exact prevalence is unknown. OBJECTIVES: Considering the lack of national data related to its diagnosis in patients with psoriasis, this study aims to describe the clinical, laboratorial and radiological manifestations of psoriatic arthritis in these patients. METHODS: We evaluated 133 patients with psoriasis, treated as outpatients. These patients were asked to fill in the forms with data about the disease and were submitted to a clinical evaluation by a dermatologist and a rheumatologist. Suspected cases of arthritis were referred for further investigation and were classified according to presence or absence of psoriatic arthritis according to CASPAR criteria. RESULTS: The number of patients with psoriatic arthritis was 47 (35%), 17 of them were new cases. There was no difference between the groups regarding the type of psoriasis, nail involvement, presence of scalp lesions and psoriatic arthritis. Patients with psoriatic arthritis had more enthesitis and dactylitis (46.7%) than those without arthritis. CONCLUSIONS: Despite the high prevalence of arthritis found, we know that results from epidemiological studies are variable, which limits their use and interpretation. We conclude that more studies are needed to draw a profile of rheumatic manifestations in our population of psoriasis patients.

show abstract

“…While this approach does not replace the need rheumatologist, help in identifying subjects for epidemiological studies and perhaps in identifying individuals who should be referred for rheumatology consultation [15,16].…”

Section: Discussionmentioning

confidence: 99%

TOPAS vs CASPAR: Applicability in expert dermatologists

Gutiérrez-Gonzalez¹,

Arturo²,

Eilen³

et al. 2016

Clin Case Rep Rev

View full text Add to dashboard Cite

Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)

Abstract: Our simplified index is very good at classifying those who are not diagnosed with PsA and those who are diagnosed with PsA.

Cited by 172 publications

References 11 publications

Promoting patient‐centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience

Promoting patient‐centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience

Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasília

TOPAS vs CASPAR: Applicability in expert dermatologists

Contact Info

Product

Resources

About